company? Let’s change
that.
Don't see your company?
Create a company profileTri Pac, Inc. is a turnkey contract development and manufacturing organization (CDMO) for aerosol, liquid, tubes, and suppository consumer goods, over-the-counter product and medical devices. Markets served include Personal Care, OTC, Medical Device, Feminine Hygiene, Sexual Health & Wellness, Household and Defense. Certifications: - ISO 13485:2016 - Med Device GMP - WHO GMP - Pharmaceutical GMP - UL Health Canada OTC - UL Retailer Certification OTC - ISO 22716:2007 - Cosmetic/ EU GMP - ISO 9001:2015 - Quality - ISO 14001: 2015 - Environmental - FDA Registered Facility - Med Device - FDA Registered Facility - OTC - EPA Registered Facility - TTB Alcohol Permit - Minority Certified Business (NMSDC) - ITAR Registered Manufacturer/ Broker - Organic Certified (NOP/ANSI) Services include: > Contract Development & Manufacturing > Aerosol | BOV | Liquid | Tube Filling > Gels | Foams | Ointments | Suppositories > Supply Chain & Inventory Management > Transfer of IP, Suitability & Methods > Regulatory Compliance > Research and Development > Validation & Stability > Quality Control & Assurance > Logistics & Fulfillment
Spring Discovery is accelerating the discovery of therapies for aging. By targeting the biological processes of aging itself, we aim to uncover new therapies for the diseases of old age — from cardiovascular to neurodegenerative disease — and increase our healthy lifespans. We've built a machine learning platform to accelerate experimentation for discovering such therapies. We're hiring! https://www.springdisc.com/#careers
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. Founded in 2000 (NASDAQ: PODD), Insulet operates with a customer-centric focus to supply high-quality products and expand the use of insulin pump therapy. Omnipod products are now available in 20+ countries around the globe. HIRING SCAM ALERT Recently, individuals impersonating Insulet Human Resources members have offered fraudulent interviews and job offers to unsuspecting candidates. To help protect you from these scam artists, please be aware that: • Insulet will never interview a candidate over RingCentral, similar messaging apps or social media (i.e. Google Hangouts, WhatsApp, Facebook Messenger, etc.), or via text message. • Insulet will never send a company check or ask an applicant to pay a fee or purchase at home work/training materials in connection with an application for employment. • Insulet will never provide excess money to an applicant and ask the applicant to write a check for repayment. If you have any doubt about a job offer or any other communication purporting to come from Insulet, please reach out to us directly at 978-600-7000. If you receive any type of communication on behalf of Insulet that seems inappropriate or suspicious, please report this activity to: www.iC3.gov or www.stopfraud.gov
The current prescription drug system is complex, inefficient, and built around misaligned incentives. We want to reimagine medication management from the ground up, with a focus on health outcomes over profits. We believe every prescription should be affordable, accessible, and adjusted to achieve maximal clinical benefit. To do so, we are building a modern technology platform that will anchor a highly differentiated approach to pharmacy benefits. This technology will power an innovative set of clinical services and exceptional member experience, which together can improve access, increase adherence, and ensure that members maximize the clinical benefit they receive from medications.
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (Trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers, and is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. View our social community guidelines here: https://www.g1therapeutics.com/social-guidelines
Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients
Tvardi is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers.
At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Here at Tapemark, we are the foremost leaders and innovators for development and manufacturing in transdermal and oral thin film drug delivery. No, really, we are. We offer a fully-integrated solution. Our services include formulation, optimization, blending, coating, converting, primary packaging, secondary cartoning, and kitting to commercially manufacture transdermal and oral thin film drugs. We have successful experience with NDA, ANDA, and 505(b)2 FDA approvals including those for Schedule I controlled substances. As a team of subject matter experts and craftsmen, we nurture our client's pharmaceutical formulation, develop it, scale it, and guide it through the FDA approval process. Tapemark is comprised of pioneering chemists, researchers, and engineers. As world experts in transdermal and oral thin film drug delivery, we offer full project management services to keep projects ahead of milestones and never behind. Tapemark has significant experience launching NDA and ANDA drugs to offer our clients the most hands-on and successful partnership in the CDMO space. Tapemark is known for its superior, truly unmatched, state-of-the-art equipment. Since the beginning, our investment has been laser-focused on owning and operating a 150,000-square-foot facility that cannot be beat in the industry. We are devoted to the industry's brightest people and most advanced equipment. We know what works. We know what doesn't. And we know where we can innovate and deliver for efficient FDA approvals and progressive timelines. The Tapemark team is powered, staffed, and driven to help clients move faster, better, and with unrivaled quality to benefit the patient and improve compliance. Our pharmaceutical products perform in the clinic and surpass FDA standards. Tapemark is privately-held and based in West St. Paul, Minnesota, with multiple facilities in a campus environment. The company services the pharmaceutical, medical, and consumer products markets.
Vertisis is one of the most unique sterile-injectable compounding pharmacies in the United States. Our focus is on going “above and beyond” traditional compounding pharmacies by raising the standards of 503A compounding pharmacies to include exceptional products, unique delivery, advanced education, and an amazing relationship with health care providers with a seamless delivery of care. Vertisis originates from over 20 years of clinical practice in custom compounded pharmaceutical agents and over 100 years of combined compounding pharmacy experience with clinical usage of the latest technologies. We have intimate knowledge of hundreds of thousands of custom compounded pharmaceutical treatments with a team of knowledgeable pharmacists to help answer your questions.
BrightSpring is the parent company of a family of services and brands that provides clinical, nonclinical, pharmacy and ancillary care services for people of all ages, health and skill levels across home and community settings. The company is a leading provider of diversified home and community-based health and pharmacy services to medically complex and high-need populations. Its primary businesses include: behavioral health (including autism services), home health care (including personal care, home health, and hospice), neuro therapy, and job placement and vocational training, supported by pharmacy and telecare ancillary technologies and services. These businesses employ over 37,000 dedicated full-time equivalent team members in 50 states and provide services for over 350,000 people every day. BrightSpring is focused on providing quality outcomes and solutions through best-in-class services and investments in people, process and technology innovation, including the development of its Connected Home model of care. Founded and headquartered in Louisville, Kentucky, the company has been making a difference in communities since 1974 – helping people live their best life.
PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare and serious disease
www.psgconsults.com. Pharmaceutical Strategies Group (PSG) is the leading pharmacy intelligence and technology company providing cutting-edge drug cost-management solutions. Drawing on more than 20 years of pharmaceutical innovation and best practices experience, we deploy proprietary technology, industry intelligence, data-enabled services and the industry’s most trusted advisors to help our clients reduce costs, enhance revenue, and optimize health outcomes. We offer a robust and holistic array of services designed to help healthcare systems, health plans, large employers and multi-employer organizations respond to the complexities of the prescription drug market and address their most pressing pharmacy management challenges. As a trusted strategic partner to more than 300 clients, we serve as an independent advocate and technology resource to help maximize their investment in pharmaceuticals. Our client-centric approach has allowed us maintain a 99.9 percent retention rate while generating over $6 billion in savings for organizations representing more than 100 million lives. Backed by a laser focus on pharmacy and unparalleled leverage in the marketplace, we deliver unbiased and actionable insights powered by analytics that enable us to ask better questions, find better answers and deliver better results.
Encysive Pharmaceuticals develops synthetic and small molecule compounds to address medical needs worldwide.
Oragenics develops oral probiotic products and antibiotics for humans and companion pets.
Exela Pharma Sciences, a fast-growing specialty pharmaceutical company, focuses on developing, manufacturing and marketing generic and proprietary injectable and sterile ophthalmic products that keep the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in people’s lives, and also meet the needs of the healthcare providers that treat them. Exela targets the development and manufacturing of generic and proprietary injectable and sterile ophthalmic products with high barriers to market entry, via an Abbreviated New Drug Approval or 505(b)(2) regulatory pathway. We develop products that enhance the patient or provider experience such as easing the burden of administration, providing an improved safety profile, faster drug preparation, or reduce drug waste. In other words, we strive to improve patient outcomes while reducing overall health care costs.
RxAnte offers predictive analytics and targeted clinical programs that improve medication prescribing and adherence.
We are located near the Texas Medical Center in Houston, Texas. Under the leadership of Alice S. Weissfeld, Ph.D., D (ABMM), and Paula H. Vance, SM(NRM), SM(ASCP), CLS(M), msi has remained in the forefront of microbiology testing since 1984 and maintains a reputation for scientifically reliable testing. Originally founded as a clinical microbiology reference laboratory, msi subsequently expanded its services to include environmental microbiology and pharmaceutical and diagnostic trials. MSI has built a strong reputation as a central microbiology lab. Our heritage of scientific and therapeutic excellence translates to the highest standards for our sponsors. Dr. Weissfeld reviews all testing methods and schema to ensure the most efficient and effective study design. We routinely add new tests and evaluate industry trends in order to build our capabilities to support client needs. We offer scientific expertise related to: Protocol consultation Veterinarian Clinical Trials Medical Device Pharmaceutical Please contact us today to discuss your Microbiology needs for any type of clinical trial or USP Compliance.
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of CNS diseases and disorders.